2026-2034年全球芽孢益生菌市場規模、佔有率、趨勢和成長分析報告

全球芽孢益生菌市場規模預計將從2025年的35億美元成長至2034年的79.5億美元，2026年至2034年的複合年成長率（CAGR）為9.54%。隨著消費者和企業日益認知到芽孢益生菌菌株的潛在益處，該市場正在不斷擴張。與許多傳統益生菌不同，芽孢菌株即使在嚴苛的儲存和加工條件下也能保持高度穩定性。這一特性使其成為膳食補充劑、機能性食品、動物飼料和特殊保健品領域的理想選擇。隨著人們對腸道和消化系統健康的日益關注，製造商正在尋求具有更高便利性、更長保存期限和柔軟性配方的高穩定性益生菌產品。

這一成長主要受消費者對腸道菌群健康、預防性營養和功能性補充劑日益成長的興趣所驅動。由於孢子型益生菌的穩定性有利於生產和分銷，因此擴大被添加到膠囊、粉末、飲料和營養產品中。動物飼料產業的需求也不斷成長，相關研究正致力於開發能夠促進消化健康和提高生產力的益生菌。製造商正加大對菌株鑑定、配方技術、臨床研究和品管流程的投入，以展現其產品的益處並在競爭激烈的市場中脫穎而出。

隨著研究不斷深入，孢子形成菌株的作用機制及其潛在的健康應用前景依然樂觀。進一步的科學支持有望推動其在主流膳食補充劑和機能性食品中的更廣泛應用。封裝技術、複合配方和標靶遞送技術的創新將進一步提升產品效能。人們對個人化營養和以微生物組為中心的醫療保健的日益關注，可能為專業配方創造更多機會。隨著法律規範和消費者認知的不斷完善，擁有強大研發能力、高品質標準和臨床驗證產品的公司將受益於未來的產業擴張。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的關鍵促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區特定分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球芽孢益生菌市場：依菌株類型分類

• 市場分析、洞察與預測
• Bacillus coagulans
• Bacillus subtilis
• Bacillus clausii
• Bacillus licheniformis
• 多菌株混合物
• 其他（新興毒株）

第5章 全球芽孢益生菌市場：依應用分類

• 市場分析、洞察與預測
• 營養補充品
• 功能性食品和飲料
• 動物飼料和水產養殖
• 藥物與臨床營養
• 其他

第6章 全球芽孢益生菌市場：以劑型分類

• 市場分析、洞察與預測
• 膠囊和軟膠囊
• 藥片
• 粉末
• 軟糖咀嚼片
• 液體/滴劑
• 其他

第7章 全球芽孢益生菌市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • IFF
  • Kerry Group
  • Sabinsa Corporation
  • Dsm-firmenich
  • Unique Biotech Ltd
  • Sanzyme Biologics
  • Wecare Probiotics Co. Ltd
  • ILDONG Bioscience
  • Chambio Co. Ltd
  • Probiotical SpA
  • Sporegen Limited
  • Microbiome Labs
  • Deerland Probiotics & Enzymes

The global spore-based probiotics market size is expected to reach USD 7.95 Billion in 2034 from USD 3.50 Billion in 2025, growing at a CAGR of 9.54% during 2026-2034.This market is expanding as consumers and businesses increasingly recognize the potential advantages of spore-forming probiotic strains. Unlike many conventional probiotic organisms, spore-based strains can demonstrate strong stability under challenging storage and processing conditions. This characteristic makes them attractive for dietary supplements, functional foods, animal nutrition, and specialized health products. Growing awareness of gut health and digestive wellness is encouraging manufacturers to explore stable probiotic formats that can provide convenience, extended shelf life, and improved formulation flexibility.

Growth is being driven by rising consumer interest in microbiome health, preventive nutrition, and functional supplementation. Spore-based probiotics are increasingly incorporated into capsules, powders, beverages, and nutritional products because their stability can support manufacturing and distribution. Demand is also developing in animal feed, where probiotics are being investigated for supporting digestive health and productivity. Manufacturers are investing in strain identification, formulation technologies, clinical research, and quality-control processes to demonstrate product benefits and differentiate their offerings in a competitive probiotic environment.

Future prospects remain favorable as research continues to clarify the mechanisms and potential health applications of spore-forming strains. Greater scientific validation could encourage broader adoption in mainstream nutritional and functional products. Innovations in encapsulation, combination formulations, and targeted delivery may further improve product performance. Growing interest in personalized nutrition and microbiome-focused healthcare could create additional opportunities for specialized formulations. As regulatory frameworks and consumer understanding evolve, companies with strong research capabilities, quality standards, and clinically supported products are likely to benefit from future industry expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Strain Type

• Bacillus coagulans
• Bacillus subtilis
• Bacillus clausii
• Bacillus licheniformis
• Multi-Strain Blends
• Others (Emerging Strains)

By Application

• Dietary Supplements
• Functional Food & Beverages
• Animal Feed & Aquaculture
• Pharmaceuticals & Clinical Nutrition
• Others

By Dosage Form

• Capsules & Softgels
• Tablets
• Powders
• Gummies & Chews
• Liquids & Drops
• Others

COMPANIES PROFILED

• IFF, Kerry Group, Sabinsa Corporation, dsm-firmenich, Unique Biotech Ltd., Sanzyme Biologics, Wecare Probiotics Co. Ltd., ILDONG Bioscience, Chambio Co. Ltd., Probiotical S.p.A., Sporegen Limited, Microbiome Labs, Deerland Probiotics & Enzymes

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SPORE-BASED PROBIOTICS MARKET: BY STRAIN TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Strain Type
• 4.2. Bacillus coagulans Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bacillus subtilis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Bacillus clausii Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Bacillus licheniformis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Multi-Strain Blends Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others (Emerging Strains) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SPORE-BASED PROBIOTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Dietary Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Functional Food & Beverages Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Animal Feed & Aquaculture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Pharmaceuticals & Clinical Nutrition Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SPORE-BASED PROBIOTICS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Dosage Form
• 6.2. Capsules & Softgels Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Powders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Gummies & Chews Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Liquids & Drops Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SPORE-BASED PROBIOTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Strain Type
  • 7.2.2 By Application
  • 7.2.3 By Dosage Form
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Strain Type
  • 7.3.2 By Application
  • 7.3.3 By Dosage Form
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Strain Type
  • 7.4.2 By Application
  • 7.4.3 By Dosage Form
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Strain Type
  • 7.5.2 By Application
  • 7.5.3 By Dosage Form
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Strain Type
  • 7.6.2 By Application
  • 7.6.3 By Dosage Form
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SPORE-BASED PROBIOTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 IFF
  • 9.2.2 Kerry Group
  • 9.2.3 Sabinsa Corporation
  • 9.2.4 Dsm-firmenich
  • 9.2.5 Unique Biotech Ltd
  • 9.2.6 Sanzyme Biologics
  • 9.2.7 Wecare Probiotics Co. Ltd
  • 9.2.8 ILDONG Bioscience
  • 9.2.9 Chambio Co. Ltd
  • 9.2.10 Probiotical S.p.A
  • 9.2.11 Sporegen Limited
  • 9.2.12 Microbiome Labs
  • 9.2.13 Deerland Probiotics & Enzymes